{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:32:48Z","timestamp":1753889568612},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Is any one combination therapy for metastatic non-small cell lung cancer (NSCLC) superior to other regimens for metastatic NSCLC? The answer is \u201cprobably no.\u201d More than 4,000 patients with advanced NSCLC participated in randomized trials presented at the 37th Annual Meeting of the American Society of Clinical Oncology. TAX326 was the only study in which the investigational arm (cisplatin\/docetaxel) showed a statistically significant difference in survival compared with the reference standard (cisplatin\/vinorelbine). We did learn, however, that what we administer may make some difference: cisplatin might be superior to carboplatin, and patients treated with nonplatinum chemotherapy regimens have a trend toward poorer survival than those who receive platinum doublets. Although there is still no clear best regimen for advanced NSCLC, we may now know how much chemotherapy to give: a randomized study presented found that four cycles produces as much survival benefit as treating until progression. The most significant abstracts presented at this year's lung cancer session involved the use of novel agents with unique mechanisms of action. The median survival in the large, randomized trials of chemotherapy in advanced NSCLC remains a bleak 9 months. ISIS 3521, an antisense oligonucleotide that targets protein kinase C, was found to produce a near doubling of survival when combined with carboplatin and paclitaxel. OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, was shown to have impressive single agent activity in the second-line treatment of lung cancer. The future of lung cancer therapy will involve combining these novel agents with active chemotherapy regimens in an effort to improve outcome.<\/jats:p>\n               <jats:p>While we appear to have reached a plateau in what we can accomplish with various combinations of cytotoxic chemotherapy in metastatic NSCLC, in locally-advanced disease new chemotherapy combinations can achieve remarkable results when combined with radiation therapy. The Southwest Oncology Group presented unprecedented phase II data on the use of cisplatin and etoposide with concurrent radiation therapy followed by consolidation docetaxel in patients with stage IIIB NSCLC.<\/jats:p>","DOI":"10.1634\/theoncologist.6-5-407","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"407-414","source":"Crossref","is-referenced-by-count":12,"title":["Lung Cancer"],"prefix":"10.1093","volume":"6","author":[{"given":"Tracey L.","family":"Evans","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Thomas J.","family":"Lynch","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2001,10,1]]},"reference":[{"key":"2021122210523880800_R1","article-title":"Phase III trial comparing three platinum-based doublets in advanced non-small cell lung cancer [Abstract 1227]. Thirty-seventh Annual Meeting of the American Society of Clinical Oncology","volume-title":"San Francisco, California, USA, 2001.","author":"Scagliotti"},{"key":"2021122210523880800_R2","article-title":"A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) [Abstract 1228]. Thirty-seventh Annual Meeting of the American Society of Clinical Oncology","volume-title":"San Francisco, California, USA, 2001.","author":"VanMeerbeeck"},{"key":"2021122210523880800_R3","article-title":"Cisplatin\/gemcitabine (CG) versus cisplatin\/gemcitabine\/vinorelbine (CGV) versus sequential doublets of gemcitabine\/vinorelbine followed by ifosfamide\/vinorelbine (GV\/IV) in advanced non-small cell lung cancer (NSCLC): results of a Spanish Lung Cancer Group phase III trial (GEPC\/98-02) [Abstract 1220]. Thirty-seventh Annual Meeting of the American Society of Clinical Oncology","volume-title":"San Francisco, California, USA, 2001.","author":"Alberola"},{"key":"2021122210523880800_R4","article-title":"A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) versus vinorelbine + cisplatin (VC) in chemotherapy-na\u00efve patients with advanced and metastatic non-small cell lung cancer [Abstract 1252]","volume-title":"Thirty-seventh Annual Meeting of the American Society of Clinical Oncology","author":"Rodriguez","year":"2001"},{"key":"2021122210523880800_R5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.2000.18.3.623","article-title":"Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial","volume":"18","author":"Bonomi","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122210523880800_R6","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122210523880800_R7","first-page":"2a","article-title":"A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)","volume-title":"Proc Annu Mtg Am Soc Clin Oncol","author":"Schiller","year":"2000"},{"key":"2021122210523880800_R8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JCO.1994.12.2.360","article-title":"Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients","volume":"12","author":"Le Chevalier","year":"1994","journal-title":"J Clin Oncol"},{"key":"2021122210523880800_R9","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group","volume":"18","author":"Fossella","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122210523880800_R10","first-page":"973a","article-title":"Randomized Pan-European trial comparing paclitaxel\/carboplatin versus paclitaxel\/cisplatin in advanced non-small cell lung cancer","volume-title":"Proc Tenth European Cancer Conference","author":"Gatzmeier","year":"1999"},{"key":"2021122210523880800_R11","article-title":"duration of therapy in stage IIIB\/IV non-small cell lung Cancer (NSCLC): a multi-institutional phase III trial [Abstract 1232]. Thirty-seventh Annual Meeting of the American Society of Clinical Oncology","volume-title":"San Francisco, California, USA, 2001.","author":"Socinski"},{"key":"2021122210523880800_R12","article-title":"Phase I\/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer [Abstract 1234]. Thirty-seventh Annual Meeting of the American Society of Clinical Oncology","volume-title":"San Francisco, California, USA, 2001.","author":"Yuen"},{"key":"2021122210523880800_R13","article-title":"A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC) [Abstract 1235]. Thirty-seventh Annual Meeting of the American Society of Clinical Oncology","volume-title":"San Francisco, California, USA, 2001.","author":"Perez-Soler"},{"key":"2021122210523880800_R14","article-title":"Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIb non-small cell lung cancer (NSCLC) (SWOG 9504): patterns of failure and updated survival [Abstract 1255]. 37th Annual Meeting of the American Society of Clinical Oncology","volume-title":"San Francisco, California, 2001","author":"Gaspar"},{"key":"2021122210523880800_R15","first-page":"1891a","article-title":"Phase III comparison of sequential vs concurrent chemoradiation for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of radiation therapy oncology group (RTOG) 9410","volume-title":"Proc Annu Mtg Am Soc Clin Oncol","author":"Curran","year":"2000"},{"key":"2021122210523880800_R16","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.1999.17.9.2692","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer","volume":"17","author":"Furuse","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122210523880800_R17","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.1997.15.2.712","article-title":"Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer","volume":"15","author":"Choi","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122210523880800_R18","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1200\/JCO.1998.16.2.622","article-title":"Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial","volume":"16","author":"Eberhardt","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122210523880800_R19","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0003-4975(98)01187-4","article-title":"Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer","volume":"66","author":"Rice","year":"1998","journal-title":"Ann Thorac Surg"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.6-5-407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.6-5-407","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/6\/5\/407\/41837558\/oncolo_6_5_407.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/6\/5\/407\/41837558\/oncolo_6_5_407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T18:25:28Z","timestamp":1640197528000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/6\/5\/407\/6386884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,1]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2001,10,1]]},"published-print":{"date-parts":[[2001,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.6-5-407","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2001,10,1]]},"published":{"date-parts":[[2001,10,1]]}}}